See more : CF Acquisition Corp. IV (CFIVU) Income Statement Analysis – Financial Results
Complete financial analysis of Decibel Therapeutics, Inc. (DBTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Decibel Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Tokyo Ichiban Foods Co., Ltd. (3067.T) Income Statement Analysis – Financial Results
- Dhunseri Tea & Industries Limited (DHUNTEAIND.BO) Income Statement Analysis – Financial Results
- Atlas Salt Inc. (REMRF) Income Statement Analysis – Financial Results
- Stellantis N.V. (STLAP.PA) Income Statement Analysis – Financial Results
- Centrum Capital Limited (CENTRUM.BO) Income Statement Analysis – Financial Results
Decibel Therapeutics, Inc. (DBTX)
About Decibel Therapeutics, Inc.
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule; DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial; AAV.103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency; AAV.104 to restore hearing in individuals with stereocilin (STRC) deficiency; and cochlear hair cell regeneration program, an AAV-based gene therapy that utilizes cell-selective expression of reprogramming factors to convert supporting cells into outer hair cells. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 40.33M | 29.85M | 25.32M | 29.41M | 26.17M |
| General & Administrative | 23.63M | 20.38M | 14.24M | 14.68M | 11.69M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 23.63M | 20.38M | 14.24M | 14.68M | 11.69M |
| Other Expenses | 0.00 | 12.00K | 171.00K | 0.00 | 0.00 |
| Operating Expenses | 63.96M | 50.23M | 39.56M | 44.08M | 37.86M |
| Cost & Expenses | 63.96M | 50.23M | 39.56M | 44.08M | 37.86M |
| Interest Income | 1.19M | 193.00K | 55.00K | 1.41M | 1.70M |
| Interest Expense | 1.19M | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.46M | 1.41M | 1.64M | 1.77M | 1.47M |
| EBITDA | -62.50M | -48.82M | -39.56M | -42.31M | -36.39M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -63.96M | -50.23M | -39.56M | -44.08M | -37.86M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.19M | 205.00K | 226.00K | 1.41M | 1.70M |
| Income Before Tax | -62.77M | -50.03M | -39.34M | -42.67M | -36.16M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 240.00K | 1.80M | -1.70M | -1.41M | 1.70M |
| Net Income | -63.01M | -51.82M | -37.64M | -41.26M | -36.16M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.52 | -2.38 | -1.63 | -5.61 | -4.98 |
| EPS Diluted | -2.52 | -2.38 | -1.63 | -5.61 | -4.98 |
| Weighted Avg Shares Out | 24.96M | 21.73M | 23.12M | 7.36M | 7.26M |
| Weighted Avg Shares Out (Dil) | 24.96M | 21.73M | 23.12M | 7.36M | 7.26M |
Decibel Therapeutics Appoints Cynthia Hu as Chief Legal Officer and Corporate Secretary
Decibel Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update
Decibel Therapeutics: Gene Therapies For Hearing Loss
Losers Outnumber Gainers in Biotech IPOs This Year
Decibel Therapeutics Expands World-Class Scientific Advisory Board
Decibel Therapeutics Reports First Quarter 2021 Financial Results and Corporate Update
Decibel Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
Decibel Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update
Decibel Therapeutics' Hearing Loss Gene Therapy Shows Potential In Preclinical Studies
Decibel Therapeutics Presents Promising Preclinical Findings on DB-OTO, Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin Mutations
Source: https://incomestatements.info
Category: Stock Reports